South Africa

The South African Health Products Regulatory Authority (SAHPRA) is the primary national regulatory body responsible for the evaluation, registration, and post-market surveillance of all health products in South Africa, including medicines, medical devices, in vitro diagnostics, and complementary medicines. SAHPRA was formally established under the Medicines and Related Substances Act 101 of 1965, as comprehensively amended by the South African Health Products Regulatory Authority Act 9 of 2019, which replaced the former Medicines Control Council (MCC). All health products must be registered with SAHPRA before they may be marketed or sold in South Africa, with applications assessed for quality, safety, and efficacy or performance. The authority operates tiered review pathways, including an expedited or priority review track for products addressing unmet medical needs or public health emergencies, as well as a reliance pathway that leverages decisions from stringent regulatory authorities such as the EMA, FDA, and Health Canada to streamline local approvals.

Applicants must appoint a local responsible pharmacist or authorised South African representative to liaise with SAHPRA and accept regulatory responsibility within the country. Pharmaceutical dossiers are accepted in Common Technical Document (CTD) format, while medical device and IVD submissions follow the African Medical Device Forum (AMDF) framework, which is broadly aligned with Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) guidance. South Africa also participates in the African Medicines Regulatory Harmonization (AMRH) initiative under the African Union Development Agency (AUDA-NEPAD), and SAHPRA is designated as a continental reference regulatory authority. Recent reforms have focused on reducing the historically significant registration backlog through procedural streamlining, increased reliance on foreign regulatory decisions, and the introduction of an online submissions portal to improve dossier management and transparency.

Public sector procurement of health products in South Africa is primarily coordinated through the National Department of Health (NDoH) in conjunction with the nine provincial health departments, which maintain significant autonomous procurement authority. At the national level, the NDoH negotiates and awards contracts through the National Tender Bid Adjudication Committee and the State Information Technology Agency (SITA) for digital health solutions, while the centralised Pharmaceutical and Medical Supplies Depot system manages warehousing and distribution. The Central Procurement Database managed under National Treasury sets compliance requirements for all suppliers, including B-BBEE (Broad-Based Black Economic Empowerment) scoring, which is a critical evaluation criterion in tender adjudication. Provincial governments issue their own tenders for commodities not covered under national contracts, creating a multi-layered procurement environment that requires engagement at both national and provincial levels. Price negotiations for medicines are informed by the Single Exit Price (SEP) mechanism, which regulates the maximum allowable price for all registered medicines sold in South Africa.

The private sector represents a substantial and sophisticated channel, accounting for a significant portion of total health expenditure and served primarily through large pharmacy chains, hospital groups (such as Mediclinic, Netcare, and Life Healthcare), and medical scheme-funded purchasing. Distributors and wholesalers, including Dis-Chem, Clicks, and Alliance Healthcare, play a central intermediary role in private market access. South Africa is also a significant recipient of donor-funded health programs, with organisations such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR (implemented through USAID), and the Bill and Melinda Gates Foundation supporting procurement of ARVs, diagnostics, and other commodities, often channeled through the NDoH or implementing partners. UNICEF Supply Division and the Clinton Health Access Initiative (CHAI) provide additional procurement and price negotiation support for specific product categories. Local manufacturing preference is actively promoted through the NDoH's Pharmaceutical Manufacturing Strategy and recent government commitments to expand domestic production capacity, incentivised further by preferential scoring in public tenders for locally manufactured or packaged products under the Preferential Procurement Policy Framework Act (PPPFA).